Amgen 2022: Operation growth strategy
Amgen is equipped with a broad and diverse product portfolio, commercial capabilities, and levers for delivering mid-single digit revenue growth over this decade.
About Andrew Humphreys
This author has not written his bio yet.
But we are proud to say that Andrew Humphreys contributed 3897 entries already.
Entries by Andrew Humphreys
GSK 2022: A newly focused biopharma company
Targeted business development acquisitions, improvements in R&D and operating performance, and a strengthened post-demerger balance sheet are creating new capacity and flexibility for GSK to invest in growth and innovation for patients and shareholders.
Johnson & Johnson 2022: Driving change, collaboration, and innovation
2022 has been marked by the first year of leadership under CEO Joaquin Duato and the anticipated separation of the company’s consumer health business.
Novartis 2022: Innovative medicines focus
A separation of Sandoz via a 100 percent spin-off will create the leading European generics company and a global leader in biosimilars, and a more focused Novartis.
Roche 2022: Portfolio renewal
A strong product pipeline and increased group sales confirm that Roche is on the right growth path.
Top 200 Medicines Report 2022: Over the top
The biopharma industry’s response to the global pandemic has propelled some COVID-19 vaccines into the leading ranks of the world’s best-selling products, with Pfizer/BioNTech’s Comirnaty surpassing AbbVie’s Humira for the No. 1 spot.
Biopharma Report 2022: Brand values surge
The values of leading pharmaceutical brands have skyrocketed during the COVID-19 pandemic; Johnson & Johnson retains the top position.
Havas Health & You Appoints Dan Rubin as President of Havas Health +
To continue to support health and wellness companies’ rapidly expanding cultural relevance and dominance of global content, Havas Health & You (HH&Y) announced that industry veteran Dan Rubin will join the network. He will work closely with global executive leadership and existing President and CCO Allison Ceraso to shape the future vision for Havas Health +, a fully integrated experience agency on the rise. Havas Health + has generated double-digit growth for the past 3 years, growing both HCP and DTC practices through new client wins and brand launches.
Strategies to Increase Diversity in Rare Genetic Disease Trials
Diversity in all clinical research—including rare disease research—is currently under scrutiny, partly because of disparities experienced with COVID-19. Rightly so, as data show that 86 percent of genomics studies to date have involved people of European ancestry, which has limited the potential benefits of genomic research for many populations. Rebecca Sutphen, Co-Founder and Chief Medical Officer of InformedDNA, and Board-Certified Genetic Counselor Karmen Trzupek analyze strategies to increase diversity in rare genetic disease trials.
Maria Fontanazza joins Outcomes LLC
Outcomes LLC, publisher of market-leading Med Ad News magazine and PharmaLive.com for the life sciences industry, strengthens its leadership team with the addition of Director of Content, Maria Fontanazza. Maria adds more than 20 years of experience in journalism, marketing, and communications. She was previously Editor-in-Chief at Innovative Publishing Company Inc., covering medical devices and additional FDA-regulated markets.
